Literature DB >> 155698

Binding phenomena of isolated unique plasmic degradation products of human cross-linked fibrin.

S A Olexa, A Z Budzynski.   

Abstract

Proteolysis of human cross-linked fibrin by plasmin results in the formation of a DD . E complex, and Fragments DD and E as the major degradation products. Three species of Fragment E, which differ both in molecular weights (E1, Mr = 60,000; E2, Mr = 55,000; E3, Mr = 50,000) and in charge, have been isolated from a digest of cross-linked fibrin. Each Fragment E species reacts with monospecific anti-E antiserum. Fragments E1 and E2 bind with Fragment DD to form a DD . E complex but Fragment E3 is inactive. This binding is specific since these Fragments E do not bind to fibrinogen or to degradation products of fibrinogen or of noncross-linked fibrin. Fragments E1 and E2 incubated with plasmin are degraded to Fragment E3, suggesting that the three species represent sequential degradation products. Plasmin-treated Fragments E1 and E2 no longer bind with Fragment DD; therefore, it appears that the peptides cleaved from Fragment E2 by plasmin contain or modify the sites responsible for complex formation. On the other hand, Fragment DD binds not only to Fragments E1 and E2, but also to fibrinogen, Fragments X (Stage 1), X (Stage 2), Y, and NH2-terminal disulfide knot, but only after thrombin treatment, suggesting that Fragment DD binds to complementary sites on the NH2-terminal region of fibrinogen which are exposed after thrombin treatment.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 155698

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Polymerization of fibrin: specificity, strength, and stability of knob-hole interactions studied at the single-molecule level.

Authors:  Rustem I Litvinov; Oleg V Gorkun; Scott F Owen; Henry Shuman; John W Weisel
Journal:  Blood       Date:  2005-07-05       Impact factor: 22.113

2.  The complementary aggregation sites of fibrin investigated through examination of polymers of fibrinogen with fragment E.

Authors:  Y Veklich; E K Ang; L Lorand; J W Weisel
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

3.  Distinctive role of histidine-16 of the B beta chain of fibrinogen in the end-to-end association of fibrin.

Authors:  A Shimizu; Y Saito; Y Inada
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

4.  The sequence A alpha-(148-160) in fibrin, but not in fibrinogen, is accessible to monoclonal antibodies.

Authors:  W J Schielen; M Voskuilen; G I Tesser; W Nieuwenhuizen
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

5.  Effect of fibrinogen, fibrin, and fibrin degradation products on transendothelial migration of leukocytes.

Authors:  Sergiy Yakovlev; Leonid Medved
Journal:  Thromb Res       Date:  2017-11-21       Impact factor: 3.944

6.  Specific uptake of radioiodinated fragment E1 by venous thrombi in pigs.

Authors:  L C Knight; S A Olexa; L S Malmud; A Z Budzynski
Journal:  J Clin Invest       Date:  1983-12       Impact factor: 14.808

7.  Evidence for four different polymerization sites involved in human fibrin formation.

Authors:  S A Olexa; A Z Budzynski
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

8.  Batroxobin binds fibrin with higher affinity and promotes clot expansion to a greater extent than thrombin.

Authors:  Trang T Vu; Alan R Stafford; Beverly A Leslie; Paul Y Kim; James C Fredenburgh; Jeffrey I Weitz
Journal:  J Biol Chem       Date:  2013-04-23       Impact factor: 5.157

9.  Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.

Authors:  J I Weitz; B Leslie; J Ginsberg
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

10.  Multiple pathways are involved in DNA degradation during keratinocyte terminal differentiation.

Authors:  M Yamamoto-Tanaka; T Makino; A Motoyama; M Miyai; R Tsuboi; T Hibino
Journal:  Cell Death Dis       Date:  2014-04-17       Impact factor: 8.469

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.